Inhibition of OXA-1 β-lactamase by penems

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3135-3143

  Bethel, Christopher R ^a   Distler, Anne M ^b   Ruszczycky, Mark W ^b   Carey, Marianne P ^b   Carey, Paul R ^b   Hujer, Andrea M ^a   Taracila, Magda ^a   Helfand, Marion S ^a,b   Thomson, Jodi M ^b   Kalp, Matthew ^b   Anderson, Vernon E ^b   Leonard, David A ^c   Hujer, Kristine M ^a   Abe, Takao ^d   Venkatesan, Aranapakam M ^d   Mansour, Tarek S ^d   Bonomo, Robert A ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Grand Valley State College   (United States)

^d WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE OXA 1; ENAMINE; ENZYME; PENEM DERIVATIVE; PIPERACILLIN; SERINE; TAZOBACTAM; THIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; CYCLIZATION; DESORPTION; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; HYDROLYSIS; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TIME OF FLIGHT MASS SPECTROMETRY;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BICYCLO COMPOUNDS; ENZYME INHIBITORS; ESCHERICHIA COLI; HETEROCYCLIC COMPOUNDS; KINETICS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 50949086970     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01677-07     Document Type: Article

References (57)

1. Adediran, S. A., M. Nukaga, S. Baurin, J. M. Frere, and R. F. Pratt. 2005. Inhibition of class D β-lactamases by acyl phosphates and phosphonates. Antimicrob. Agents Chemother. 49:4410-4412.
2. Afzal-Shah, M., N. Woodford, and D. M. Livermore. 2001. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 45:583-588.
3. Aubert, D., L. Poirel, J. Chevalier, S. Leotard, J. M. Pages, and P. Nordmann. 2001. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 45:1615-1620.
4. Barlow, M., and B. G. Hall. 2002. Phylogenetic analysis shows that the OXA β-lactamase genes have been on plasmids for millions of years. J. Mol. Evol. 55:314-321.
5. Beadle, B. M., I. Trehan, P. J. Focia, and B. K. Shoichet. 2002. Structural milestones in the reaction pathway of an amide hydrolase: substrate, acyl, and product complexes of cephalothin with AmpC β-lactamase. Structure 10:413-424.
6. Bell, R. P. 1959. The proton in chemistry. Cornell University Press, Ithaca, NY.
7. Bonomo, R. A., J. Liu, Y. Chen, L. Ng, A. M. Hujer, and V. E. Anderson. 2001. Inactivation of CMY-2 β-lactamase by tazobactam: initial mass spectroscopic characterization. Biochim. Biophys. Acta 1547:196-205.
8. Bradford, P. A. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951.
9. Broom, N. J. P., T. H. Farmer, F. N. Osborne, and J. W. Tyler. 1992. Studies on the mechanism of action of (5R)-(Z)-6-(1 methyl-1,2,3-triazol-4-yl methylene) penem-3-carboxylic acid (BRL 42715), a potent inhibitor of bacterial β-lactamase. J. Chem. Soc. Chem. Commun. 22:1663-1664.
10. Brown, S., and S. Amyes. 2006. OXA β-lactamases in Acinetobacter: the story so far. J. Antimicrob. Chemother. 57:1-3.
11. Bulychev, A., I. Massova, S. A. Lerner, and S. Mobashery. 1995. Penem BRL 42715: an effective inactivator for β-lactamases. J. Am. Chem. Soc. 117: 4797-4801.
12. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
13. De Meester, F., B. Joris, G. Reckinger, C. Bellefroid-Bourguignon, J. M. Frere, and S. G. Waley. 1987. Automated analysis of enzyme inactivation phenomena. Application to β-lactamases and DD-peptidases. Biochem. Pharmacol. 36:2393-2403.
14. Dubois, V., C. Arpin, C. Quentin, J. Texier-Maugein, L. Poirel, and P. Nordmann. 2003. Decreased susceptibility to cefepime in a clinical strain of Escherichia coli related to plasmid- and integron-encoded OXA-30 β-lactamase. Antimicrob. Agents Chemother. 47:2380-2381.
15. Farmer, T. H., J. W. Page, D. J. Payne, and D. J. Knowles. 1994. Kinetic and physical studies of β-lactamase inhibition by a novel penem, BRL 42715. Biochem. J. 303(Pt 3):825-830.
16. Fisher, J. F., S. O. Meroueh, and S. Mobashery. 2005. Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105:395-424.
17. VIM-1-containing integron from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 49:1973-1980.
18. Golemi, D., L. Maveyraud, S. Vakulenko, J. P. Samama, and S. Mobashery. 2001. Critical involvement of a carbamylated lysine in catalytic function of class D β-lactamases. Proc. Natl. Acad. Sci. USA 98:14280-14285.
19. Helfand, M. S., C. R. Bethel, A. M. Hujer, K. M. Hujer, V. E. Anderson, and R. A. Bonomo. 2003. Understanding resistance to β-lactams and β-lactamase inhibitors in the SHV β-lactamase: lessons from the mutagenesis of SER-130. J. Biol. Chem. 278:52724-52729.
20. Helfand, M. S., and R. A. Bonomo. 2003. β-Lactamases: a survey of protein diversity. Curr. Drug Targets Infect. Disord. 3:9-23.
21. Helfand, M. S., M. A. Totir, M. P. Carey, A. M. Hujer, R. A. Bonomo, and P. R. Carey. 2003. Following the reactions of mechanism-based inhibitors with β-lactamase by Raman crystallography. Biochemistry 42:13386-13392.
22. Hujer, A. M., K. M. Hujer, and R. A. Bonomo. 2001. Mutagenesis of amino acid residues in the SHV-1 β-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance. Biochim. Biophys. Acta 1547:37-50.
23. Kalp, M., A. Sheri, J. D. Buynak, C. R. Bethel, R. A. Bonomo, and P. R. Carey. 2007. Efficient inhibition of class A and class D β-lactamases by Michaelis complexes. J. Biol. Chem. 282:21588-21591.
24. Kaye, K. S., H. S. Gold, M. J. Schwaber, L. Venkataraman, Y. Qi, P. C. De Girolami, M. H. Samore, G. Anderson, J. K. Rasheed, and F. C. Tenover. 2004. Variety of β-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United States. Antimicrob. Agents Chemother. 48:1520-1525.
25. Kuzin, A. P., M. Nukaga, Y. Nukaga, A. Hujer, R. A. Bonomo, and J. R. Knox. 2001. Inhibition of the SHV-1 β-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. Biochemistry 40:1861-1866.
26. Lakaye, B., A. Dubus, S. Lepage, S. Groslambert, and J. M. Frere. 1999. When drug inactivation renders the target irrelevant to antibiotic resistance: a case story with β-lactams. Mol. Microbiol. 31:89-101.
27. Leonard, D. A., A. M. Hujer, B. A. Smith, K. D. Schneider, C. R. Bethel, K. M. Hujer, and R. A. Bonomo. 2008. The role of OXA-1 β-lactamase Asp(66) in the stabilization of the active-site carbamate group and in substrate turnover. Biochem. J. 410:455-462.
28. Livermore, D. M. 1995. β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.
29. Livermore, D. M. 1997. β-Lactamases: quantity and resistance. Clin. Microbiol. Infect. 3(Suppl. 4):S10-S19.
30. Lobkovsky, E., E. M. Billings, P. C. Moews, J. Rahil, R. F. Pratt, and J. R. Knox. 1994. Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a β-lactamase transition-state analog. Biochemistry 33:6762-6772.
31. Majumdar, S., S. A. Adediran, M. Nukaga, and R. F. Pratt. 2005. Inhibition of class D β-lactamases by diaroyl phosphates. Biochemistry 44:16121-16129.
32. Mansour, T. S., A. Agarwal, A. Venkatesan, T. Abe, A. Mihira, T. Takasaki, K. Sato, H. Ushirogochi, I. Yamaura, T. Isoda, Z. Li, Y. Yang, and T. Kumagai. 2007. On the absolute configuration in 1,4-dihydrothiazepine covalent complexes derived from inhibition of class A and class C β-lactamases with 6-methylidene penem. ChemMedChem 2:1713-1716.
33. Matagne, A., P. Ledent, D. Monnaie, A. Felici, M. Jamin, X. Raquet, M. Galleni, D. Klein, I. Francois, and J. M. Frere. 1995. Kinetic study of interaction between BRL 42715, β-lactamases, and D-alanyl- D-alanine peptidases. Antimicrob. Agents Chemother. 39:227-231.
34. Maveyraud, L., D. Golemi-Kotra, A. Ishiwata, O. Meroueh, S. Mobashery, and J. P. Samama. 2002. High-resolution X-ray structure of an acyl-enzyme species for the class D OXA-10 β-lactamase. J. Am. Chem. Soc. 124:2461-2465.
35. Maveyraud, L., D. Golemi, L. P. Kotra, S. Tranier, S. Vakulenko, S. Mobashery, and J. P. Samama. 2000. Insights into class D β-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. Structure 8:1289-1298.
36. Michaux, C., P. Charlier, J. M. Frere, and J. Wouters. 2005. Crystal structure of BRL 42715, C6-(N1-methyl-1,2,3-triazolylmethylene)penem, in complex with Enterobacter cloacae 908R β-lactamase: evidence for a stereoselective mechanism from docking studies. J. Am. Chem. Soc. 127:3262-3263.
37. OXA-53) and 6′-N-aminoglycoside acetyltransferase genes [aac(6′)- I30]. J. Antimicrob. Chemother. 54:354-359.
38. Navia, M. M., J. Ruiz, and J. Vila. 2002. Characterization of an integron carrying a new class D β-lactamase (OXA-37) in Acinetobacter baumannii. Microb. Drug Resist. 8:261-265.
39. NCCLS. 2005. Performance standards for antimicrobial disk susceptibility testing. Fifteenth informational supplement. NCCLS document M100-S15. NCCLS, Wayne, PA.
40. NCCLS. 2003. Performance standards for antimicrobial disk susceptibility tests. Approved standard, 8th ed. NCCLS document M2-A8. NCCLS, Wayne, PA.
41. Nukaga, M., T. Abe, A. M. Venkatesan, T. S. Mansour, R. A. Bonomo, and J. R. Knox. 2003. Inhibition of class A and class C β-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate. Biochemistry 42:13152-13159.
42. Padayatti, P. S., A. Sheri, M. A. Totir, M. S. Helfand, M. P. Carey, V. E. Anderson, P. R. Carey, C. R. Bethel, R. A. Bonomo, J. D. Buynak, and F. van den Akker. 2006. Rational design of a β-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 Å crystal structure of wt SHV-1 complex with a penam sulfone. J. Am. Chem. Soc. 128:13235-13242.
43. Pagan-Rodriguez, D., X. Zhou, R. Simmons, C. R. Bethel, A. M. Hujer, M. S. Helfand, Z. Jin, B. Guo, V. E. Anderson, L. M. Ng, and R. A. Bonomo. 2004. Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130→Gly SHV-1 β-lactamase: insights into the mechanism of inhibition. J. Biol. Chem. 279:19494-19501.
44. Poirel, L., D. Girlich, T. Naas, and P. Nordmann. 2001. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob. Agents Chemother. 45:447-453.
45. Poirel, L., and P. Nordmann. 2002. Acquired carbapenem-hydrolyzing β-lactamases and their genetic support. Curr. Pharm. Biotechnol. 3:117-127.
46. Prumal, S. K., and R. F. Pratt. 2006. Synthesis and evaluation of ketophosph(on)ates as β-lactamase inhibitors J. Org. Chem. 71:4778-4785.
47. Richter, H. G., P. Angehrn, C. Hubschwerlen, M. Kania, M. G. Page, J. L. Specklin, and F. K. Winkler. 1996. Design, synthesis, and evaluation of 2 β-alkenyl penam sulfone acids as inhibitors of β-lactamases. J. Med. Chem. 39:3712-3722.
48. Rule, C. K., and V. K. LaMer. 1938. Dissociation constants of deutero acids by e.m.f. measurements,. J. Am. Chem. Soc. 60:1974-1981.
49. Schowen, K. B. J. 1978. Solvent hydrogen isotope effects. Plenum Press, New York, NY.
50. Stapleton, P., P. J. Wu, A. King, K. Shannon, G. French, and I. Phillips. 1995. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob. Agents Chemother. 39:2478-2483.
51. Sulton, D., D. Pagan-Rodriguez, X. Zhou, Y. Liu, A. M. Hujer, C. R. Bethel, M. S. Helfand, J. M. Thomson, V. E. Anderson, J. D. Buynak, L. M. Ng, and R. A. Bonomo. 2005. Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 β-lactamase. Insights into the mechanism of inhibition. J. Biol. Chem. 280:35528-35536.
52. Sun, T., M. Nukaga, K. Mayama, E. H. Braswell, and J. R. Knox. 2003. Comparison of β-lactamases of classes A and D: 1.5-Å crystallographic structure of the class D OXA-1 oxacillinase. Protein Sci. 12:82-91.
53. Thomson, J. M., A. M. Distler, F. Prati, and R. A. Bonomo. 2006. Probing active site chemistry in SHV β-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. J. Biol. Chem. 281:26734-26744.
54. Totir, M. A., P. S. Padayatti, M. S. Helfand, M. P. Carey, R. A. Bonomo, P. R. Carey, and F. van den Akker. 2006. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine β-lactamase intermediates. Biochemistry 45:11895-11904.
55. 7 R stereochemistry by computational methods. J. Med. Chem. 49:4623-4637.
56. Venkatesan, A. M., Y. Gu, O. Dos Santos, T. Abe, A. Agarwal, Y. Yang, P. J. Petersen, W. J. Weiss, T. S. Mansour, M. Nukaga, A. M. Hujer, R. A. Bonomo, and J. R. Knox. 2004. Structure-activity relationship of 6-methylidene penems bearing tricyclic heterocycles as broad-spectrum β-lactamase inhibitors: crystallographic structures show unexpected binding of 1,4-thiazepine intermediates. J. Med. Chem. 47:6556-6568.
57. Walther-Rasmussen, J., and N. Hoiby. 2006. OXA-type carbapenemases. J. Antimicrob. Chemother. 57:373-383.